Breakthrough drug trial offers hope for devastating brain disorder
NCT ID NCT07498426
Summary
This study aims to test whether the experimental drug NIO752 can slow the progression of Progressive Supranuclear Palsy (PSP), a rare and serious brain disorder that affects movement and balance. The trial will involve 300 adults aged 41-81 with mild to moderate PSP symptoms. Participants will receive either NIO752 or a placebo for part of the study, followed by an open period where everyone can receive the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY RICHARDSON SYNDROME (PSP-RS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.